No CrossRef data available.
Article contents
Dyskinesia in Parkinson Disease - An Unmet Therapeutic Challenge
Published online by Cambridge University Press: 02 December 2014
Abstract
An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
- Type
- Editorial
- Information
- Copyright
- Copyright © The Canadian Journal of Neurological 2012
References
1.Encarnacion, EV, Hauser, RA.Levodopa-induced dyskinesias in Parkinson’s Disease: etiology, impact on quality of life, and treatments. Eur Neurol. 2008;60:57–66.CrossRefGoogle ScholarPubMed
2.Hametner, E, Seppi, K, Poewe, W.The clinical spectrum of levodopa-induced motor complications. J Neurol. 2010;257 Suppl 2: S268–75.CrossRefGoogle ScholarPubMed
3.Gottwald, MD, Aminoff, MJ.Therapies for dopaminergic-induced dyskinesias in Parkinson disease. Ann Neurol. 2011;69:919–27.Google Scholar
4.Jenner, P.Molecular mechanisms of L-DOPA-induced dyskinesia. Nat Rev Neurosci. 2008;9(9):665–77.CrossRefGoogle ScholarPubMed
5.Iravani, MM, Jenner, P.Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation. J Neural Transm. 2011;118:1661–90.Google Scholar
6.Ahmed, I, Bose, SK, Pavese, N, et al.Glutamate NMDA receptor dysregulation in Parkinson’s disease with dyskinesias. Brain. 2011;134:979–86.CrossRefGoogle ScholarPubMed
7.Chase, TN, Oh, JD.Striatal dopamine- and glutamate mediated dysregulation in experimental parkinsonism. Trends Neurosci. 2000;23 Suppl 10:S86–91.Google Scholar
8.Hubsher, G, Haider, M, Okun, MS.Amantadine: the journey from fighting flu to treating Parkinson disease. Neurology. 2012;78(14):1096–9.Google Scholar
9.Pahwa, R, Factor, SA, Lyons, KE, et al.Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006;66:983–95Google Scholar
10.Elahi, B, Phielipp, N, Chen, R.N-Methyl-D-Aspartate antagonists in levodopa induced dyskinesia: a meta-analysis. Can J Neurol Sci. 2012;39(4):465–72.CrossRefGoogle ScholarPubMed
11.Stathis, P, Konitsiotis, S, Tagaris, G, Peterson, D, VALID-PD Study Group. Levetiracetam for the management of levodopa-induced dyskinesia in Parkinson’s disease. Mov Disord. 2011;26(2):264–70.CrossRefGoogle ScholarPubMed
12.Lane, E, Dunnett, S.Animal models of Parkinson’s disease and L-dopa induced dyskinesia: how close are we to the clinic? Psychopharmacology. 2008;199(3):303–12.Google Scholar
You have
Access